PHVS
Pharvaris N.V.
Biotechnology
Market Cap$1.96B
5Y Perf.-20.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PHVS vs KALV
Revenue, margins, valuation, and 5-year total return — side by side.
KALV
KalVista Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.37B
5Y Perf.-18.7%
PHVS vs KALV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PHVS | KALV |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.96B | $1.37B |
| Revenue (TTM) | $0.00 | $15M |
| Net Income (TTM) | $-166M | $-210M |
| Gross Margin | — | -17.2% |
| Operating Margin | — | -13.4% |
| Total Debt | $861K | $6M |
| Cash & Equiv. | $281M | $99M |
PHVS vs KALV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PHVS
KALV
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| Pharvaris N.V. (PHVS) | 100 | 79.3 | -20.7% |
| KalVista Pharmaceut… (KALV) | 100 | 81.3 | -18.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PHVS vs KALV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PHVS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. KalVista Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PHVS
Pharvaris N.V.
The Growth Play
PHVS carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 5.7%
- Lower volatility, beta 1.02, Low D/E 0.3%, current ratio 12.60x
- -23.2% revenue growth vs KALV's -34.5%
Best for: growth exposure and sleep-well-at-night
KALV
KalVista Pharmaceuticals, Inc.
The Income Pick
KALV is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.82
- 156.2% 10Y total return vs PHVS's 3.8%
- Beta 0.82, current ratio 5.35x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PHVS | -23.2% revenue growth vs KALV's -34.5% |
| Quality / Margins | PHVS | 1.9% margin vs KALV's -13.9% |
| Stability / Safety | KALV | Beta 0.82 vs PHVS's 1.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KALV | +113.9% vs PHVS's +78.9% |
| Efficiency (ROA) | PHVS | -49.0% ROA vs KALV's -77.7% |
PHVS vs KALV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPHVSLAGGINGKALV
KALVKalVista Pharmaceutic…
1leads
PHVSPharvaris N.V.
3leads
6 Total Categories
CATEGORYLEADERvs KALVMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PHVS1/1
Valuation MetricsMultiples, price ratios, and targets
PHVS2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PHVS6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
KALV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PHVS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KALV and PHVS operate at a comparable scale, with $15M and $0 in trailing revenue.
| Metric | PHVSPharvaris N.V. | KALVKalVista Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $15M |
| EBITDAEarnings before interest/tax | -$86M | -$202M |
| Net IncomeAfter-tax profit | -$166M | -$210M |
| Free Cash FlowCash after capex | -$134M | -$160M |
| Gross MarginGross profit ÷ Revenue | — | -17.2% |
| Operating MarginEBIT ÷ Revenue | — | -13.4% |
| Net MarginNet income ÷ Revenue | — | -13.9% |
| FCF MarginFCF ÷ Revenue | — | -10.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +22.1% | -1.1% |
PHVS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
PHVS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | PHVSPharvaris N.V. | KALVKalVista Pharmace… |
|---|---|---|
| Market CapShares × price | $2.0B | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -10.35x | -7.24x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 5.18x | 13.91x |
| Price / FCFMarket cap ÷ FCF | — | — |
PHVS leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
PHVS leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
PHVS delivers a -53.2% return on equity — every $100 of shareholder capital generates $-53 in annual profit, vs $-3 for KALV. PHVS carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KALV's 0.07x. On the Piotroski fundamental quality scale (0–9), KALV scores 2/9 vs PHVS's 1/9, reflecting mixed financial health.
| Metric | PHVSPharvaris N.V. | KALVKalVista Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -53.2% | -2.8% |
| ROA (TTM)Return on assets | -49.0% | -77.7% |
| ROICReturn on invested capital | — | -152.3% |
| ROCEReturn on capital employed | -44.7% | -89.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.07x |
| Net DebtTotal debt minus cash | -$280M | -$92M |
| Cash & Equiv.Liquid assets | $281M | $99M |
| Total DebtShort + long-term debt | $861,470 | $6M |
| Interest CoverageEBIT ÷ Interest expense | — | -13.75x |
PHVS leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — PHVS and KALV each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PHVS five years ago would be worth $12,371 today (with dividends reinvested), compared to $10,783 for KALV. Over the past 12 months, KALV leads with a +113.9% total return vs PHVS's +78.9%. The 3-year compound annual growth rate (CAGR) favors PHVS at 48.1% vs KALV's 41.0% — a key indicator of consistent wealth creation.
| Metric | PHVSPharvaris N.V. | KALVKalVista Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | +13.7% | +72.8% |
| 1-Year ReturnPast 12 months | +78.9% | +113.9% |
| 3-Year ReturnCumulative with dividends | +225.2% | +180.1% |
| 5-Year ReturnCumulative with dividends | +23.7% | +7.8% |
| 10-Year ReturnCumulative with dividends | +3.8% | +156.2% |
| CAGR (3Y)Annualised 3-year return | +48.1% | +41.0% |
Evenly matched — PHVS and KALV each lead in 3 of 6 comparable metrics.
Risk & Volatility
KALV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KALV is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than PHVS's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | PHVSPharvaris N.V. | KALVKalVista Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.02x | 0.82x |
| 52-Week HighHighest price in past year | $31.12 | $26.84 |
| 52-Week LowLowest price in past year | $14.59 | $9.83 |
| % of 52W HighCurrent price vs 52-week peak | +96.8% | +99.5% |
| RSI (14)Momentum oscillator 0–100 | 56.8 | 75.4 |
| Avg Volume (50D)Average daily shares traded | 223K | 3.0M |
KALV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PHVS as "Buy" and KALV as "Buy". Consensus price targets imply 45.0% upside for PHVS (target: $44) vs 6.7% for KALV (target: $29).
| Metric | PHVSPharvaris N.V. | KALVKalVista Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $43.67 | $28.50 |
| # AnalystsCovering analysts | 11 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PHVS leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). KALV leads in 1 (Risk & Volatility). 1 tied.
Best OverallPharvaris N.V. (PHVS)Leads 3 of 6 categories
Loading custom metrics...
PHVS vs KALV: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PHVS or KALV a better buy right now?
Analysts rate Pharvaris N.
V. (PHVS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PHVS or KALV?
Over the past 5 years, Pharvaris N.
V. (PHVS) delivered a total return of +23. 7%, compared to +7. 8% for KalVista Pharmaceuticals, Inc. (KALV). Over 10 years, the gap is even starker: KALV returned +156. 2% versus PHVS's +3. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PHVS or KALV?
By beta (market sensitivity over 5 years), KalVista Pharmaceuticals, Inc.
(KALV) is the lower-risk stock at 0. 82β versus Pharvaris N. V. 's 1. 02β — meaning PHVS is approximately 24% more volatile than KALV relative to the S&P 500. On balance sheet safety, Pharvaris N. V. (PHVS) carries a lower debt/equity ratio of 0% versus 7% for KalVista Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PHVS or KALV?
On earnings-per-share growth, the picture is similar: Pharvaris N.
V. grew EPS 5. 7% year-over-year, compared to -7. 3% for KalVista Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PHVS or KALV?
Pharvaris N.
V. (PHVS) is the more profitable company, earning 0. 0% net margin versus -1391. 1% for KalVista Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHVS leads at 0. 0% versus -1343. 0% for KALV. At the gross margin level — before operating expenses — PHVS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PHVS or KALV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PHVS or KALV better for a retirement portfolio?
For long-horizon retirement investors, KalVista Pharmaceuticals, Inc.
(KALV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82), +156. 2% 10Y return). Both have compounded well over 10 years (KALV: +156. 2%, PHVS: +3. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PHVS and KALV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.